Clinical-stage biopharmaceutical company Mersana Therapeutics Inc. (MRSN:NASDAQ), which is focused on discovering and developing antibody-drug conjugates (ADCs) targeting cancers, today reported "interim safety, tolerability and efficacy data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma." Members of the company's executive team held a conference call earlier today together with investigator Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute, to present and discuss the trial data. The firm indicated that the data will be presented to the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020.
The company's President and CEO Anna Protopapas commented, "These data demonstrate not only that XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, can deliver confirmed complete responses, partial responses and durable stable disease in platinum-resistant ovarian cancer, but also that these responses can deepen over time in a patient population with poor prognosis and limited treatment options...XMT-1536 continues to demonstrate that it is generally well tolerated, without the dose-limiting toxicities of other ADC platforms such as severe neutropenia, neuropathy and ocular toxicity. These are encouraging signals as we look forward to reporting more mature data in the second half of the year and continuing to advance XMT-1536 for both platinum-resistant ovarian cancer and NSCLC adenocarcinoma patients."
The firm advised that "the expansion portion of the Phase 1 study is enrolling patients with platinum-resistant ovarian cancer, fallopian tube or primary peritoneal cancer who have received up to three lines of prior therapy and in some cases four lines of prior therapy regardless of platinum status as well as patients with NSCLC adenocarcinoma who had received prior treatment with platinum-based therapy and immunotherapy or targeted agents." The company stated that the interim data reported covered 34 patients including 27 with ovarian cancer and 7 with NSCLC adenocarcinoma.
The company highlighted some of the key findings in the study including that XMT-153 achieved a 35% objective response rate, including 10% complete response rate and 80% disease control rate among 20 evaluable patients with ovarian cancer.The firm stated that XMT-1536's safety profile was consistent with previously reported dose escalation data and no new safety signals were observed. Additionally, the firm advised that promising antitumor activity was observed in platinum-resistant ovarian cancer and that the data continue to support a NaPi2b biomarker-based patient selection strategy.
Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Mass., that utilizes its proprietary ADC platforms to develop novel ADCs with the goal of achieving optimal efficacy, safety and tolerability to improve the lives of individuals fighting cancer. In addition to XMT-1536, which is currently being tested in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma, the company also has a second ADC product candidate, XMT-1592, that is targeting NaPi2b-expressing tumors. The firm advised that XMT-1592 was created using its Dolasynthen platform and is in the dose escalation portion of a Phase 1 clinical study.
Mersana Therapeutics started off the day with a market capitalization of around $634.3 million with approximately 58.95 million shares outstanding and a short interest of about 4.0%. MRSN shares opened 45% higher today at $15.68 (+$4.90, +45.45%) over yesterday's $10.78 closing price and reached a new 52-week high price of $18.50. The stock has traded today between $13.26 and $18.50 per share and is currently trading at $17.55 (+$6.79, +63.10%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
